{"protocolSection": {"identificationModule": {"nctId": "NCT01252810", "orgStudyIdInfo": {"id": "GE 145-002"}, "organization": {"fullName": "GE Healthcare", "class": "INDUSTRY"}, "briefTitle": "Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure", "officialTitle": "A Phase 2, Double-Blind, Randomized, Safety Study of GE-145 320 mg I/mL Injection Versus Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Artery Catheterization Procedure"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-11"}, "primaryCompletionDateStruct": {"date": "2012-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-12-01", "studyFirstSubmitQcDate": "2010-12-01", "studyFirstPostDateStruct": {"date": "2010-12-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-02-06", "resultsFirstSubmitQcDate": "2014-04-02", "resultsFirstPostDateStruct": {"date": "2014-05-02", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-08-01", "lastUpdatePostDateStruct": {"date": "2018-08-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GE Healthcare", "class": "INDUSTRY"}, "collaborators": [{"name": "i3 Statprobe", "class": "INDUSTRY"}, {"name": "Medpace, Inc.", "class": "INDUSTRY"}, {"name": "Biomedical Systems", "class": "INDUSTRY"}, {"name": "Rules-Based Medicine, Inc.", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus (DM) requiring drug therapy, or congestive heart failure (CHF) NYHA Class III or greater, who are referred for a coronary catheterization procedure with or without PCI."}, "conditionsModule": {"conditions": ["Chronic Renal Insufficiency", "Diabete Mellitus", "Congestive Heart Failure"], "keywords": ["CATH Catheterization", "CI-AKI Contrast-induced acute kidney injury", "DM Diabetes mellitus", "eGFR Estimated glomerular filtration rate", "MDRD Modification of Diet in Renal Disease", "NYHA New York Heart Association", "PCI Percutaneous coronary intervention", "SCr Serum creatinine"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 284, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "GE 145 320mg I/ml injection", "type": "EXPERIMENTAL", "interventionNames": ["Drug: GE-145"]}, {"label": "Iopamidol 370mg I/ml injection", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: GE-145"]}], "interventions": [{"type": "DRUG", "name": "GE-145", "description": "GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.", "armGroupLabels": ["GE 145 320mg I/ml injection", "Iopamidol 370mg I/ml injection"], "otherNames": ["Ioforminol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Comparison of Overall Image Quality Between Ioforminol and Iopamidol-enhanced Images as Determined by an Independent Reader.", "description": "Overall image quality (excellent, adequate or poor) and diagnostic usefulness (diagnostic or non-diagnostic) were assessed using qualitative scales.", "timeFrame": "After the imaging date for either Ioforminol or Iopamidol."}], "secondaryOutcomes": [{"measure": "To Determine Incidence Rates of the Overall AEs, Organ-specific AEs (i.e., Delayed Skin Reactions, General Subject Comfort, and Allergic/Immunologic Reactions, Etc.) and SAEs Following Administration", "description": "To determine incidence rates of the overall AEs, organ-specific AEs (i.e., delayed skin reactions, general subject comfort, and allergic/immunologic reactions, etc.) and SAEs following administration of GE-145 or iopamidol.\n\nTo determine incidence rates and onset time of biomarker-based and SCr-based CI-AKI following administration of GE-145 or iopamidol.\n\nSummary of Treatment-Emergent Adverse Events (TEAE) in greater than of equal to 2% of Subjects.", "timeFrame": "Time zero equals the date of contrast imaging and for up to 7 days for safety monitoring post contrast administration."}, {"measure": "Assessing the Incidence of Renal Biomarker-based Contrast-induced Acute Kidney Injury (CI-AKI) in Subjects Post Administration of Ioforminol or Iopamidol Injections", "description": "Analyzing the number of subjects with renal biomarker-based contrast-induced acute kidney injury (CI-AKI).", "timeFrame": "2, 6 and 24 hours post Ioforminol and Iopamidol adminstration"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Males and females 65 years of age with cardiovascular disease who are referred for a coronary catheterization procedure with or without PCI.\n* The subject has at least one of the following comorbidities:\n* 1) Chronic renal insufficiency, (eGFR \\<60 but 15 mL/min/1.73 m2 according to the MDRD equation) as measured within 2 weeks or at the screening visit;\n* 2) DM diagnosed greater than 6 months prior to study entry and which requires either insulin or anti-hyperglycemic drug therapy;\n* 3) CHF (NYHA) class III or greater measured within 2 weeks of enrollment or at the screening visit.\n\nExclusion Criteria:\n\n* The subject has known allergies to either iodine or any ICM.\n* The subject has severe renal insufficiency (eGFR \\<15 mL/min/1.73 m2 according to the MDRD equation) or is on dialysis.\n* The subject has acute coronary syndrome requiring emergency coronary angiography and/or intervention.\n* The subject is not willing or unable to discontinue metformin (e.g., Glucophage) at the time of the study procedure.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "65 Years", "stdAges": ["OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Rubin Sheng, M.D.", "affiliation": "GE Healthcare", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GE Healthcare", "city": "Princeton", "state": "New Jersey", "zip": "08540", "country": "United States", "geoPoint": {"lat": 40.34872, "lon": -74.65905}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Ioforminol 320mg I/ml Injection", "description": "Ioforminol 320 mg I/mL as a single iv. administration."}, {"id": "FG001", "title": "Iopamidol 370mg I/ml Injection", "description": "Iopamidol 370 mg I/mL as a single iv. administration."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "142"}, {"groupId": "FG001", "numSubjects": "142"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "128"}, {"groupId": "FG001", "numSubjects": "139"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Various reasons", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Ioforminol 320mg I/ml Injection", "description": "Ioforminol 320 mg I/mL as a single iv. administration."}, {"id": "BG001", "title": "Iopamidol 370mg I/ml Injection", "description": "Iopamidol 370 mg I/mL as a single iv. administration."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "137"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "278"}]}], "measures": [{"title": "Age, Categorical", "description": "Per a Protocol Amendment, A-01, the minimum age changed to male or female greater than or equal to 18 years of age who have a history of chronic renal insufficiently.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "58"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "109"}, {"groupId": "BG001", "value": "111"}, {"groupId": "BG002", "value": "220"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "53"}, {"groupId": "BG002", "value": "101"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "89"}, {"groupId": "BG001", "value": "88"}, {"groupId": "BG002", "value": "177"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "128"}, {"groupId": "BG001", "value": "134"}, {"groupId": "BG002", "value": "262"}]}]}, {"title": "Canada", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "16"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Comparison of Overall Image Quality Between Ioforminol and Iopamidol-enhanced Images as Determined by an Independent Reader.", "description": "Overall image quality (excellent, adequate or poor) and diagnostic usefulness (diagnostic or non-diagnostic) were assessed using qualitative scales.", "populationDescription": "The measured values are looking at 1) Overall Image Quality and, 2) Diagnostic Usefulness.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of subjects", "timeFrame": "After the imaging date for either Ioforminol or Iopamidol.", "groups": [{"id": "OG000", "title": "Ioforminol 320mg I/ml Injection", "description": "Ioforminol 320 mg I/mL as a single iv. administration."}, {"id": "OG001", "title": "Iopamidol 370mg I/ml Injection", "description": "Iopamidol 370 mg I/mL as a single iv. administration."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "141"}]}], "classes": [{"title": "Overall Image Quality-Excellent", "categories": [{"measurements": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "71"}]}]}, {"title": "Overall Image Quality-Adequate", "categories": [{"measurements": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "59"}]}]}, {"title": "Overal Image Quality-Poor", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "11"}]}]}, {"title": "Diagnostic Usefulness-Diagnostic", "categories": [{"measurements": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "134"}]}]}, {"title": "Diagnostic Usefulness-Non-Diagnostic", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "7"}]}]}]}, {"type": "SECONDARY", "title": "To Determine Incidence Rates of the Overall AEs, Organ-specific AEs (i.e., Delayed Skin Reactions, General Subject Comfort, and Allergic/Immunologic Reactions, Etc.) and SAEs Following Administration", "description": "To determine incidence rates of the overall AEs, organ-specific AEs (i.e., delayed skin reactions, general subject comfort, and allergic/immunologic reactions, etc.) and SAEs following administration of GE-145 or iopamidol.\n\nTo determine incidence rates and onset time of biomarker-based and SCr-based CI-AKI following administration of GE-145 or iopamidol.\n\nSummary of Treatment-Emergent Adverse Events (TEAE) in greater than of equal to 2% of Subjects.", "populationDescription": "Summary of Treatment-Emergent Adverse Events (TEAE) in greater than of equal to 2% of Subjects.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of events", "timeFrame": "Time zero equals the date of contrast imaging and for up to 7 days for safety monitoring post contrast administration.", "groups": [{"id": "OG000", "title": "Ioforminol 320mg I/ml Injection", "description": "Ioforminol 320 mg I/mL as a single iv. administration."}, {"id": "OG001", "title": "Iopamidol 370mg I/ml Injection", "description": "Iopamidol 370 mg I/mL as a single iv. administration."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "141"}]}], "classes": [{"title": "Angina Pectoris", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Coronary Artery Disease", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Diarrhea", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Nausea", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Catheter-Site Hematoma", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Catheter-Site Hemorrhage", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Catheter-Site Pain", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Chest Pain", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Urinary Tract Infection", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Blood Creatinine Increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Pain In Extremity", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Dizziness", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Headache", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Assessing the Incidence of Renal Biomarker-based Contrast-induced Acute Kidney Injury (CI-AKI) in Subjects Post Administration of Ioforminol or Iopamidol Injections", "description": "Analyzing the number of subjects with renal biomarker-based contrast-induced acute kidney injury (CI-AKI).", "populationDescription": "Summary of subjects with renal biomarker-based CI-AKI by time point (Per Protocol Population).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "2, 6 and 24 hours post Ioforminol and Iopamidol adminstration", "groups": [{"id": "OG000", "title": "Ioforminol 320mg I/ml Injection", "description": "Ioforminol 320 mg I/mL as a single iv. administration."}, {"id": "OG001", "title": "Iopamidol 370mg I/ml Injection", "description": "Iopamidol 370 mg I/mL as a single iv. administration."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "106"}]}], "classes": [{"title": "Time- Post Contrast, 2 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "21"}]}]}, {"title": "Time- Post Contrast, 6 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "33"}]}]}, {"title": "Time- Post Contrast, 24 hourss", "categories": [{"measurements": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "49"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 7 days post Ioforminol and Iopamidol administrations.", "eventGroups": [{"id": "EG000", "title": "Ioforminol 320mg I/ml Injection", "description": "Ioforminol 320 mg I/mL as a single iv. administration. Up to 7 days post Iopamidol administration.", "seriousNumAffected": 13, "seriousNumAtRisk": 137, "otherNumAffected": 20, "otherNumAtRisk": 137}, {"id": "EG001", "title": "Iopamidol 370mg I/ml Injection", "description": "Iopamidol 370 mg I/mL as a single iv. administration. Up to 7 days post Ioforminol administration.", "seriousNumAffected": 10, "seriousNumAtRisk": 141, "otherNumAffected": 9, "otherNumAtRisk": 141}], "seriousEvents": [{"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}]}, {"term": "Aortic stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}]}, {"term": "Congestive cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 141}]}, {"term": "Coronary artery disease and hospitalization", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}]}, {"term": "Unstable angina", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}]}, {"term": "Vascular pseudoaneurysm to hospitalization", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}]}, {"term": "Dyspnea", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}]}, {"term": "Hematoma", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}]}, {"term": "Coronary artery bypass", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}]}, {"term": "Cardiac pacemaker insertion to hospitalization", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}]}], "otherEvents": [{"term": "Catheter-Site Hemotoma", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Site of Administration", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 9, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 8, "numAffected": 8, "numAtRisk": 141}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 137}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Ruben Sheng, M.D.", "organization": "GE Healthcare", "email": "Rubin.Sheng@ge.com", "phone": "609-514-6899"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000051437", "term": "Renal Insufficiency"}, {"id": "D000051436", "term": "Renal Insufficiency, Chronic"}, {"id": "D000006333", "term": "Heart Failure"}, {"id": "D000003920", "term": "Diabetes Mellitus"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000007674", "term": "Kidney Diseases"}, {"id": "D000014570", "term": "Urologic Diseases"}, {"id": "D000052776", "term": "Female Urogenital Diseases"}, {"id": "D000005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000052801", "term": "Male Urogenital Diseases"}, {"id": "D000002908", "term": "Chronic Disease"}, {"id": "D000020969", "term": "Disease Attributes"}, {"id": "D000010335", "term": "Pathologic Processes"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M28998", "name": "Acute Kidney Injury", "relevance": "LOW"}, {"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabete Mellitus", "relevance": "HIGH"}, {"id": "M10698", "name": "Kidney Diseases", "relevance": "LOW"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Congestive Heart Failure", "relevance": "HIGH"}, {"id": "M26717", "name": "Renal Insufficiency, Chronic", "asFound": "Chronic Renal Insufficiency", "relevance": "HIGH"}, {"id": "M26718", "name": "Renal Insufficiency", "asFound": "Renal Insufficiency", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M17319", "name": "Urologic Diseases", "relevance": "LOW"}, {"id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW"}, {"id": "M27093", "name": "Female Urogenital Diseases", "relevance": "LOW"}, {"id": "M14127", "name": "Pregnancy Complications", "relevance": "LOW"}, {"id": "M8399", "name": "Female Urogenital Diseases and Pregnancy Complications", "relevance": "LOW"}, {"id": "M27095", "name": "Male Urogenital Diseases", "relevance": "LOW"}, {"id": "M6147", "name": "Chronic Disease", "relevance": "LOW"}, {"id": "M22700", "name": "Disease Attributes", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": true}